Monte Rosa Therapeutics Inc (GLUE) News

Form 4 - Statement of changes in beneficial ownership of securities

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

BOSTON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage...

Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study

MRT-6160, a potent and highly selective VAV1-directed molecular glue degrader, represents a potential novel...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Monte Rosa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

IND clearance achieved for MRT-6160, a VAV1-directed MGD in development for systemic and neurological...

Form 4 - Statement of changes in beneficial ownership of securities

Monte Rosa Therapeutics to Present at the UBS Targeted Protein Degradation Day

BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage...

Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160

Ongoing Phase 1/2 Study of MRT-2359 for MYC-driven solid tumors demonstrates favorable safety and...

Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis

MRT-6160, a VAV1-directed molecular glue degrader (MGD), inhibits disease progression, pro-inflammatory...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities